## Note
nid: 1557511434501
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_2::Cheesy_Dorian_(M3), #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#Physeo::09_Pharm::12_Reproductive::12_Micturition_Control, #AK_Step1_v11::#Pixorize::03_Pharm::03_Anticholinergics::Oxybutynin_Solifenacin_Tolterodine, #AK_Step2_v11::!Shelf::#Cards_AnKing_Skipped, #AK_Step2_v11::#Resources_by_rotation::tests_dorian::sa1, #AK_Step2_v11::#Subjects::Nephrology_&_Urology::01_Kidneys::Urinary_Incontinence, #AK_Step2_v11::#Subjects::Nephrology_&_Urology::01_Kidneys::Urinary_Incontinence::Urge_Incontinence::Management, #AK_Step2_v11::Original_decks::Dorian::step2::sa1
markdown: false

### Text
<div>
  Bladder training, mirabegron and oxybutynin is used to treat
  {{c1::urge}} incontinence
</div>

### Extra
<div>
  <div style="font-style: italic; font-weight: bold;"></div>
  <div style="font-weight: bold;"></div><i>- <u>first-line</u>
  treatment should consist of <b>lifestyle modifications + bladder
  training</b>; a newer agent, <b>mirabegron</b>
  (Î²<sub>3</sub>-adrenergic agonist) may be offered to patients who
  cannot take antimuscarinic drugs (e.g. narrow angle glaucoma)</i>
</div>
<div>
  <i>- think about training the bladder to not be so
  hyperactive</i>
</div>
<div style="font-weight: bold;"><img src="good%20start.png"></div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_3.png"></a>
</div>

### Additional Resources


### One by one

